The Germany-based pharmaceutical company is the result of the take-over of Schering AG by Bayer AG in 2006. The Bayer Schering Pharma AG is part of the Bayer HealthCare AG, which represents the pharmaceutical part of the Bayer Group.
The company makes ultrasound, x-ray and MRI contrast media, drugs for treating cancer, multiple-sclerosis, heart and nervous system disorders and severe skin conditions.
In general, its activities are focused on four business areas: Fertility control & hormone therapy, diagnostics & radiopharmaceuticals, dermatology as well as specialized therapeutics for disabling diseases in the fields of the central nervous system, oncology and cardiovascular system.
Currently, Bayer Schering Pharma discontinued the manufacturing and development of ultrasound contrast agents.

Ultrasound Contrast Agents:

A bolus is a rapid infusion of high dose contrast agent. Dynamic and accumulation phase imaging can be performed after bolus injection. Since the transit time of the bolus is only a short time, images with high frame rate show the wash in and wash out of the contrast material. The injection rate and the total injected volume modifies the bolus peak profile. Substantial changes in the concentrations during signal acquisition induce artifacts. Furthermore, the hemodynamic parameters (cardiac output, blood pressure) influence the bolus profile. However, the characteristics of ultrasound contrast agents are favorable with a continuous perfusion.

See also Negative Bolus.

Cavitation is any activity of highly compressible transient or stable microbubbles of gas and/or vapour, generated by ultrasonic power in the propagation medium. Cavitation can be described as inertial or non-inertial. Inertial cavitation has the most potential to damage tissue and occurs when a gas-filled cavity grows, during pressure rarefaction of the ultrasound pulse, and contracts, during the compression phase. Collapses of bubbles can generate local high temperatures and pressures. Transient cavitation can cause tissue damage.
The threshold for cavitation is high and does not occur at current levels of diagnostic ultrasound. The introduction of contrast agents leads to the formation of microbubbles that potentially provide gas nuclei for cavitation. The use of contrast agents can lower the threshold at which cavitation occurs.

Types of cavitation:

Contrast agents improve the sensitivity of vascular Doppler ultrasound, for example in cerebrovascular sonography or examinations of deep abdominal vessels. They also enlarge the role of transcranial Doppler. Microbubbles can be used with various modes e.g., color and power Doppler imaging, as well as pulsed-wave Doppler to increase the signal intensity. However, the ultrasound system must be suitable for contrast enhanced technology.
Microbubbles usually stay within the vascular space; nevertheless, the contrast enhancement is limited to 2−6 minutes caused by physiologic clearance and bubble destruction.
Depended on the application, contrast agents can be administered with a different injection rate e.g., bolus injection, slow injection, or continuous infusion. Stable, homogeneous, and prolonged enhancement can be obtained with perfusion, lasting until the infusion is stopped.

See also Cerebrovascular Ultrasonography, Multiple Frame Trigger.

A contrast medium (or contrast agent) is a chemical substance applied to the anatomical or functional region being imaged, to increase the differences between different tissues or between normal and abnormal tissue.
The chemical composition of the contrast media determines the specific usage. The intention in the development of ultrasound contrast media is a high contrast between blood and tissues in different organs or even tumors.

See also ultrasound contrast agents, the info sheet gives an overview and more in-depth information about different types of ultrasound contrast medium.